Presentación
NEPHROLOGY


nefrologia@idipaz.es

Excellent Group
Composition
Name
Composition
Institution
María Gemma Fernández Juárez
Jefe de Servicio de Nefrología
Hospital Universitario La Paz
María José Castro Notario
Enfermera
Hospital Universitario La Paz
Olga Costero Fernández
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
Gloria del Peso Gilsanz
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
María Elena González García
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
Carlos Jiménez Martín
Jefe de Sección de Nefrología
Hospital Universitario La Paz
María Ovidia López Oliva
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
Almudena Pérez Torres
Dietista-Nutricionista
Hospital Universitario Santa Cristina
Begoña Rivas Becerra
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
Amir Shabaka Fernández 
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
Rafael Jesús Sánchez Villanueva
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
Strategic Objective
The strategic objective of this care-research group is toenable, by developing a deep understanding of the various components that make up nephrology (kidney diseases in initial stages, progression of kidney disease, particular and general complications of dialysis and kidney transplantation), access by affected patients to the best diagnostic and therapeutic interventions available at any time. Each of the areas must ensure a minimum level of research and development activity representing the innovation in these areas. The lines of research are at times cross-sectional to the four components indicated for nephrology.
Research Lines
The lines of research are occasionally cross-sectional to the four components indicated for nephrology as a whole.

A) Glomerular nephropathies:
 
- Role of PLA2r levels in membranous nephropathy.
- Study of the alternative pathway of complement in glomerular pathologies: vasculitis, membranous nephropathy, IgA glomerulonephritis... 
- Morbidity, mortality and progression of diabetic nephropathy and other glomerular nephropathies.
- Adult polycystic kidney disease. Family studies and therapeutic approaches.
- Association between cardiovascular disease and progression of nephropathies (NEFRONA multicenter studies).
 
 
B) Renal replacement therapy:
 
- Evolution of peritoneal function in peritoneal dialysis. Implications for patient and technique survival. New peritoneal dialysis devices and solutions. Aquaporin 1 and its genetic polymorphisms. Involvement of alternatively activated macrophages and CC
- Cardiovascular risk in dialysis patients. Study of endocrine alterations in dialysis patients. Role of FGF 21 in uremic insulin resistance.
- Mouse model for peritoneal dialysis: exploration of the effects of dialysis fluids, pharmacological interventions and genetic manipulation (KO, transgenic).
 
C) Complications of renal transplantation.
 
- Infection and CMV disease in renal transplantation. Personalized treatment. 
- Graft tolerance.
- Quality of life of the transplanted patient. Patient-reported transplant outcome. 
- Individualization of immunosuppression. 
- Knowledge of graft cortical microcirculation. 
- Continuous active collaboration with the Spanish renal transplant group (SENTRA), some led by the La Paz group: Covid disease, renal prevention (iSGLT-2), pregnancy in renal transplantation, bacterial infections, thrombotic microangiopathy, asystole donation, relapses of different renal diseases after transplantation...